Statera Biopharma, Inc. STAB
We take great care to ensure that the data presented and summarized in this overview for Statera Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STAB
View all-
Dowling & Yahnke LLC San Diego, CA28.9KShares$00.0% of portfolio
-
Tucker Asset Management LLC Littleton, CO1KShares$00.0% of portfolio
-
Four Thought Financial, LLC Venice, FL125Shares$00.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in STAB
Top Purchases
Top Sells
About STAB
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
Insider Transactions at STAB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2021
|
Taunia Markvicka Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Sep 09
2021
|
Randy S. Saluck Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+49.94%
|
-
|
|
Sep 09
2021
|
Lea Verny Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Sep 09
2021
|
Steve K Barbarick Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Jul 27
2021
|
Michael K Handley President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
296,609
+50.0%
|
-
|
|
Jul 27
2021
|
Peter Aronstam Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
141,370
+50.0%
|
-
|
|
Jul 27
2021
|
Cozette M. Mc Avoy Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,947
+50.0%
|
-
|
|
Jul 27
2021
|
Clifford Selsky Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,579
+50.0%
|
-
|
|
Jul 27
2021
|
Robert Buckheit Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,378
+50.0%
|
-
|
|
Jul 22
2021
|
Langdon L Miller Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$30,000
$3.0 P/Share
|